With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support today during our fall member drive.
A drug based on LSD appears to treat depression in mice without the psychedelic trip
AILSA CHANG, HOST:
Drugs like magic mushrooms and LSD can act as powerful antidepressants, but they also produce mind-bending side effects. Well, NPR's Jon Hamilton reports on a drug based on LSD that appears to treat depression in mice without taking the animals on a trip.
JON HAMILTON, BYLINE: Antidepressants like Prozac act on the brain's serotonin system. So do psychedelic drugs. But with psychedelics, the effect can occur in hours instead of weeks and last for months. Brian Shoichet from the University of California, San Francisco, says the best evidence so far involves people with depression who take psilocybin, the active ingredient in magic mushrooms.
BRIAN SHOICHET: There's really interesting reports about people getting great results out of this after just a few doses.
HAMILTON: One study found the results can last a year or more, perhaps because the drug causes the brain to rewire. Psychedelic drugs, though, require medical supervision and a therapist to guide a patient through their hallucinatory experience. Shoichet says that's an impractical way to treat millions of people with depression.
SHOICHET: The society would like a molecule that you can, you know, get prescribed and just take - you know, go home and take, and you don't need a guided tour for your trip.
HAMILTON: So Shoichet and a large team of researchers are looking for that molecule. They started with a virtual collection of about 75 million hypothetical drugs likely to act on the brain's serotonin system. Shoichet says ultimately, the scientists focused on just two.
SHOICHET: They had the best properties. They were the most potent, and when you gave them to a mouse, they got into the brain at high concentrations.
HAMILTON: A test of one of these drugs found it did seem to relieve depression in mice. A depressed mouse tends to give up quickly when placed in an uncomfortable situation like being dangled from its tail. But the same mouse will keep struggling if it gets an antidepressant drug like Prozac, ketamine or psilocybin. Dr. Bryan Roth, a psychiatrist at UNC-Chapel Hill and another member of the team, says the molecule based on LSD had a similar effect.
BRYAN ROTH: We found our compound had essentially the same antidepressant activity, at least acutely - so one day later.
HAMILTON: But were those mice tripping? Apparently not. Psychedelic drugs cause mice to twitch frequently in a distinctive way. And Roth says that wasn't the case with mice that got the team's LSD-based compound.
ROTH: We were, I would say, surprised to see that they had no psychedelic drug-like actions at all.
HAMILTON: Studies in people are still a ways off. Even so, Roth says the approach points to a class of depression drugs that would have a huge advantage over products like Prozac and Zoloft, which are taken every day.
ROTH: The difference with psychedelics and the compounds that we're excited about is that it's basically one and done. Patients basically take one dose, and then they're fine.
HAMILTON: That's an optimistic view, says David Olson of the University of California, Davis. Olson, who helped create a non-psychedelic version of the drug Ibogaine, says he's skeptical that a single dose of these new compounds can eliminate depression.
DAVID OLSON: But I do think they take us a step closer to a cure, rather than simply treating disease symptoms.
HAMILTON: Olson says drugs based on psychedelics have the potential to help people who haven't responded to existing antidepressants. And because they work immediately, he says, they could be integrated into a psychotherapy session.
OLSON: You might imagine a day where a patient could take one of these drugs at home and then interact with their therapist via virtual platform like Zoom.
HAMILTON: The new research appears in the journal Nature.
Jon Hamilton, NPR News. Transcript provided by NPR, Copyright NPR.
At LAist, we believe in journalism without censorship and the right of a free press to speak truth to those in power. Our hard-hitting watchdog reporting on local government, climate, and the ongoing housing and homelessness crisis is trustworthy, independent and freely accessible to everyone thanks to the support of readers like you.
But the game has changed: Congress voted to eliminate funding for public media across the country. Here at LAist that means a loss of $1.7 million in our budget every year. We want to assure you that despite growing threats to free press and free speech, LAist will remain a voice you know and trust. Speaking frankly, the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news in our community.
We’re asking you to stand up for independent reporting that will not be silenced. With more individuals like you supporting this public service, we can continue to provide essential coverage for Southern Californians that you can’t find anywhere else. Become a monthly member today to help sustain this mission.
Thank you for your generous support and belief in the value of independent news.

-
If California redistricts, the conservative beach town that banned LGBTQ Pride flags on city property would get a gay, progressive Democrat in Congress.
-
Most survivors of January's fires face a massive gap in the money they need to rebuild, and funding to help is moving too slowly or nonexistent.
-
Kevin Lacy has an obsession with documenting California’s forgotten and decaying places.
-
Restaurants share resources in the food hall in West Adams as Los Angeles reckons with increasing restaurant closures.
-
It will be the second national day of protest against President Donald Trump.
-
The university says the compact, as the Trump administration called it, could undermine free inquiry and academic excellence.